Evidence map›Paper›PMID 40243591›Full record

ArticleInternational journal of molecular sciences2025

Berberine Derivative Compound 13 as a Potent Promoter of Osteoblast Differentiation via Akt and PKC Signaling Pathways.

Meiyu Piao, Youn Ho Han, Kwang Youl Lee

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Meiyu PiaoResearch Institute of Pharmaceutical Sciences, College of Pharmacy, Chonnam National University, Gwangju 61186, Republic of Korea.ORCID 0009-0001-8191-4343
Youn Ho HanDepartment of Oral Pharmacology, College of Dentistry, Wonkwang University, Iksan 54538, Republic of Korea.ORCID 0000-0002-7564-1350
Kwang Youl LeeResearch Institute of Pharmaceutical Sciences, College of Pharmacy, Chonnam National University, Gwangju 61186, Republic of Korea.

Funding

Wonkwang University 2024
6 · The paper itself

Abstract

Berberine has been widely studied for its biological functions in various diseases, including cancer, diabetes, and cardiovascular diseases. Nevertheless, structural modifications of berberine have been demonstrated to augment its pharmacological efficacy in specific biological processes, particularly osteogenesis. In this study, we aimed to explore new berberine derivatives with pro-osteogenic activity and molecular mechanisms. Our results demonstrated that compound

Indexed as

BerberineCell DifferentiationOsteoblastsOsteogenesisProtein Kinase CProto-Oncogene Proteins c-aktSignal TransductionAlkaline PhosphataseAnimalsCore Binding Factor Alpha 1 SubunitHumansMiceMolecular Docking SimulationSp7 Transcription FactorAlkaline PhosphataseBerberineCore Binding Factor Alpha 1 SubunitProtein Kinase CProto-Oncogene Proteins c-aktSp7 Transcription FactorAktberberinecompound 13osteoblast differentiationPKC

Identifiers

PMID40243591
PMCPMC11989097

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.